About 5 DOSES: MENINGOCOCCAL (GROUPS A, C, Y, W, X), TETANUS TOXOID AND CRM197 CONJUGATE VACCINE: EACH 0.5ML DOSE CONTAINS 5MCG EACH OF MENINGOCOCCAL A, C, Y, W AND X POLYSACCHARIDE CONJUGATED TO A CARRIER PROTEIN. A AND X POLYSACCHARIDES ARE CONJUGATED TO PURIFIED TETANUS TOXOID (TT) AND THE SEROGROUP C, W, AND Y POLYSACCHARIDES ARE CONJUGATED TO RECOMBINANT CRM197.
Meningococcal conjugate vaccine
Used for Prevention of invasive meningococcal disease caused by groups A, C, Y, W, and X Usual adult dose One 0.5 mL intramuscular dose; booster doses depend on risk and local guidance.
Usual dose in children One 0.5 mL intramuscular dose from the age specified in the local product information; schedule depends on age and risk.
Common side effects Injection-site pain, redness, or swelling Headache Fatigue Fever Important warnings Do not give to anyone with a severe allergic reaction to a previous dose or vaccine component. Vaccination may not protect against meningococcal disease caused by other groups. Use caution in people with bleeding disorders or significant immune suppression. Defer vaccination during severe acute illness when appropriate. Pregnancy Human pregnancy data are limited; use when protection is considered necessary under local guidance.
Breastfeeding Effects during breastfeeding are not well established; vaccination may be considered when indicated.
Interactions Other vaccines may be given at the same visit at separate injection sites. Immune-suppressing treatments may reduce the vaccine response. AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.
Report this summary